Hereditary antithrombin deficiency
MONDO:0013144A rare, genetic, hematological disease characterized by decreased levels of antithrombin activity in plasma resulting in impaired inactivation of thrombin and factor Xa. Patients have an increased risk for venous thromboembolism, usually in the deep veins of the arms, legs and pulmonary system and, on occasion, in other venous territories (e.g. cerebral veins or sinus, mesenteric, portal, hepatic, renal and/or retinal veins).
Also known as: AT3D, Antithrombin Deficiency, antithrombin 3 deficiency, antithrombin III deficiency, congenital AT-III deficiency, congenital antithrombin III deficiency, hereditary antithrombin deficiency, hereditary thrombophilia due to congenital antithrombin 3 deficiency
7 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New hope for rare clotting disorder: drug aims to prevent dangerous clots during surgery and delivery
Disease control Recruiting nowThis study tests a drug called Atenativ in people with a rare inherited condition that raises their risk of dangerous blood clots. The goal is to see if Atenativ can prevent clots during surgery or childbirth. About 38 adults and some teens will take part. The drug is given as an…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug could help heart surgery patients who Don't respond to standard blood thinner
Disease control Recruiting nowThis study tests a drug called Atenativ, made from human plasma, in 120 adults who are resistant to heparin during planned heart surgery. Heparin is a blood thinner used to prevent clots during surgery, but some patients don't respond well. The drug aims to restore heparin's effe…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Are doctors prescribing antithrombin correctly? a new study investigates
Knowledge-focused Recruiting nowThis study looks back at how antithrombin, a blood-clotting protein, was prescribed to 160 intensive care patients at Strasbourg University Hospitals over two years. Researchers want to see if these prescriptions were appropriate and how the drug was used in real-world settings. …
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Scientists dig into genetic roots of rare bleeding disorders
Knowledge-focused Recruiting nowThis study looks at how blood cells interact and what goes wrong in inherited bleeding disorders like Glanzmann thrombasthenia. Researchers will analyze blood samples from up to 60 healthy volunteers and patients to find genetic defects. The goal is to better understand these con…
Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC